Holen Sie sich die Stockscreener-App
3.225
9.69%
0.285
Schlusskurs vom Vortag:
$2.94
Offen:
$3.02
24-Stunden-Volumen:
248.42K
Relative Volume:
0.80
Marktkapitalisierung:
$139.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.66M
KGV:
-1.0416
EPS:
-3.0963
Netto-Cashflow:
$-97.76M
1W Leistung:
+26.47%
1M Leistung:
+60.45%
6M Leistung:
-29.12%
1J Leistung:
-76.18%
1-Tages-Spanne:
$3.02
$3.30
1-Wochen-Bereich:
$2.55
$3.30
52-Wochen-Spanne:
$1.78
$16.64
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Firmenname
Kyverna Therapeutics Inc
Sektor
Branche
Telefon
(510) 626-8331
Adresse
5980 HORTON STREET, EMERYVILLE
Vergleichen Sie KYTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
3.22 | 113.67M | 0 | -110.66M | -97.76M | -3.0963 |
|
ONC
Beone Medicines Ltd Adr
|
257.11 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.60 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2699 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.69 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
495.10 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-03-04 | Eingeleitet | JP Morgan | Overweight |
| 2024-03-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-04 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Millennium Management LLC - MarketBeat
Short Interest in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Rises By 20.6% - MarketBeat
Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 4,990 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Ameriprise Financial Inc. Raises Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts - TipRanks
BNP Paribas Financial Markets Purchases 17,786 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Northern Trust Corp Purchases 61,757 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Buy" at HC Wainwright - MarketBeat
Kyverna Therapeutics to Present at the Jefferies Global Healthca - GuruFocus
Autoimmune Cell Therapy Pioneer Kyverna Therapeutics Takes Stage at Major Jefferies Conference - Stock Titan
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Kyverna Therapeutics’ KYV-101: Promising Developments and First-to-Market Potential in Autoimmune Diseases - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to “Buy” at HC Wainwright - Defense World
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
Kyverna Therapeutics Shares Rise After Upgrade From HC Wainwright - marketscreener.com
HC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX) - Nasdaq
Kyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position - TipRanks
HC Wainwright Upgrades Kyverna Therapeutics to Buy From Neutral, Adjusts Price Target to $5 From $4 - marketscreener.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
HC Wainwright Issues Pessimistic Estimate for KYTX Earnings - MarketBeat
Analysts Offer Predictions for KYTX Q1 Earnings - MarketBeat
HC Wainwright Issues Pessimistic Outlook for KYTX Earnings - Defense World
Analysts Issue Forecasts for KYTX Q1 Earnings - Defense World
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
Jacobs Levy Equity Management Inc. Buys 442,090 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Sphera Funds Management LTD. - MarketBeat
Integral Health Asset Management LLC Purchases 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Leerink Partnrs Has Positive Outlook of KYTX Q2 Earnings - Defense World
Stifel Financial Corp Buys New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Kyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPO - Bloomberg Law News
Kyverna planning to launch Phase 3 trial of KYV-101 in MG patients - Myasthenia Gravis News
With 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investors - Yahoo Finance
Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace - Fierce Biotech
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases - Seeking Alpha
Kyverna Therapeutics Provides Business Update And Reports First Quarter 2025 Financial Results - marketscreener.com
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - PR Newswire
Kyverna's Autoimmune Pipeline Hits Major Milestones: SPS Trial Full, MG Phase 3 Gets FDA Green Light - Stock Titan
Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Tuesday - Defense World
KYTX Stockholders Have Opportunity to Lead Kyverna Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Barclays PLC Acquires 19,419 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - ACCESS Newswire
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Finanzdaten der Kyverna Therapeutics Inc-Aktie (KYTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):